国家卫健委叫停两项手术，涉阿尔茨海默病、糖尿病

Core Viewpoint - The National Health Commission of China has issued notifications to prohibit the use of "cervical deep lymphatic-venous anastomosis" for Alzheimer's treatment and "ileal-jejunal anastomosis" for type 2 diabetes treatment due to safety and efficacy concerns [1][2][5][6]. Group 1: Alzheimer's Disease and Surgical Procedures - The "cervical deep lymphatic-venous anastomosis" (LVA) is considered to be in the early exploratory stage of clinical research, lacking clear indications and contraindications, as well as high-quality evidence for safety and efficacy [1][5]. - Alzheimer's disease, characterized by cognitive dysfunction and behavioral impairment, affects over 50 million people globally, with no effective cure currently available [3][5]. - The procedure's complexity and the risks associated with the delicate nature of lymphatic vessels raise concerns about its potential benefits versus risks, especially for patients with mild symptoms [4][5]. Group 2: Type 2 Diabetes and Surgical Procedures - The "ileal-jejunal anastomosis" has been evaluated and found to have uncertain safety and efficacy for treating type 2 diabetes, with potential severe complications such as liver failure and malnutrition [6][7]. - Although some studies suggest that this procedure may lower blood sugar levels post-surgery, it remains in the exploratory phase and has not been included in the latest diabetes management guidelines [7][8]. - The National Health Commission emphasizes the need for rigorous oversight and management of clinical applications of these surgical techniques, urging local health authorities to enforce the cessation of their use [2][8].